Stock Scorecard
Stock Summary for CRISPR Therapeutics AG (CRSP) - $47.49 as of 6/30/2025 3:02:34 PM EST
Total Score
6 out of 30
Safety Score
46 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CRSP
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CRSP
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CRSP
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CRSP
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CRSP (46 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 7 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CRSP
Financial Details for CRSP
Company Overview |
|
|---|---|
| Ticker | CRSP |
| Company Name | CRISPR Therapeutics AG |
| Country | USA |
| Description | CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 47.49 |
| Price 4 Years Ago | 75.78 |
| Last Day Price Updated | 6/30/2025 3:02:34 PM EST |
| Last Day Volume | 5,194,320 |
| Average Daily Volume | 2,970,708 |
| 52-Week High | 63.68 |
| 52-Week Low | 30.04 |
| Last Price to 52 Week Low | 58.09% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 60.05 |
| Sector PE | 40.73 |
| 5-Year Average PE | -10.04 |
| Free Cash Flow Ratio | 17.46 |
| Industry Free Cash Flow Ratio | 19.19 |
| Sector Free Cash Flow Ratio | 32.54 |
| Current Ratio Most Recent Quarter | 15.64 |
| Total Cash Per Share | 2.72 |
| Book Value Per Share Most Recent Quarter | 21.18 |
| Price to Book Ratio | 2.24 |
| Industry Price to Book Ratio | 18.77 |
| Sector Price to Book Ratio | 30.79 |
| Price to Sales Ratio Twelve Trailing Months | 108.86 |
| Industry Price to Sales Ratio Twelve Trailing Months | 48.41 |
| Sector Price to Sales Ratio Twelve Trailing Months | 35.57 |
| Analyst Buy Ratings | 12 |
| Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
| Total Shares Outstanding | 86,364,000 |
| Market Capitalization | 4,101,426,360 |
| Institutional Ownership | 76.58% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -138.43% |
| Reported EPS 12 Trailing Months | -4.49 |
| Reported EPS Past Year | -1.58 |
| Reported EPS Prior Year | -4.37 |
| Net Income Twelve Trailing Months | -385,657,000 |
| Net Income Past Year | -366,252,000 |
| Net Income Prior Year | -153,610,000 |
| Quarterly Revenue Growth YOY | 71.60% |
| 5-Year Revenue Growth | -34.47% |
| Operating Margin Twelve Trailing Months | -17,159.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 235,184,000 |
| Total Cash Past Year | 298,257,000 |
| Total Cash Prior Year | 389,477,000 |
| Net Cash Position Most Recent Quarter | 235,184,000 |
| Net Cash Position Past Year | 298,257,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 1,932,080,000 |
| Total Stockholder Equity Prior Year | 1,882,803,000 |
| Total Stockholder Equity Most Recent Quarter | 1,829,160,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -307,859,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.56 |
| Free Cash Flow Past Year | -144,675,000 |
| Free Cash Flow Prior Year | -272,345,000 |
Options |
|
| Put/Call Ratio | 0.41 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 2.39 |
| MACD Signal | 1.90 |
| 20-Day Bollinger Lower Band | 32.08 |
| 20-Day Bollinger Middle Band | 40.75 |
| 20-Day Bollinger Upper Band | 49.43 |
| Beta | 1.74 |
| RSI | 68.40 |
| 50-Day SMA | 44.39 |
| 150-Day SMA | 52.67 |
| 200-Day SMA | 58.16 |
System |
|
| Modified | 6/30/2025 9:27:25 PM EST |